Moxifloxacin Concentration and Proteomic Analysis of Aqueous Humor in Human Uveitis Associated with Oral Moxifloxacin Therapy

David M Hinkle1, *, Nicole A Kruh-Garcia2, Jonathan N Kruh3, Carolyn Broccardo4, Priyanka Doctor5, C Stephen Foster5, 6, 7
1 Department of Ophthalmology, University of Massachusetts Medical School, Worcester, Massachusetts, USA
2 Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado, USA,
3 Jamaica Hospital Medical Center, Queens, New York, USA
4 Research Integrity and Compliance Review Office, Colorado State University, Colorado, USA
5 Massachusetts Eye Research and Surgery Institution, Cambridge, Massachusetts, USA
6 Ocular Inflammation and Uveitis Foundation, Cambridge, Massachusetts, USA
7 Harvard Medical School, Boston, Massachusetts, USA

Article Metrics

CrossRef Citations:
Total Statistics:

Full-Text HTML Views: 4644
Abstract HTML Views: 2490
PDF Downloads: 923
ePub Downloads: 699
Total Views/Downloads: 8756
Unique Statistics:

Full-Text HTML Views: 1912
Abstract HTML Views: 1154
PDF Downloads: 593
ePub Downloads: 455
Total Views/Downloads: 4114

Creative Commons License
© 2017 Hinkle et al.

open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

* Address correspondence to this author at the UMass Memorial Eye Center, 281 Lincoln Street, Worcester, MA 01605, USA; Tel: 508-334-4629, Fax 508-334-4655, E-mail:



The aim was to report the aqueous humor moxifloxacin concentration and proteome profile of an individual with bilateral uveitis-like syndrome with pigment dispersion.


Multiple reactions monitoring mass spectrometry quantified the aqueous concentration of moxifloxacin in the affected individual. Shotgun proteomic analysis performed via liquid chromatography tandem mass spectrometry (LC-MS/MS) defined the protein profile in the affected individual and unaffected control samples.


Moxifloxacin was present at higher than expected levels in aqueous humor 18 days following oral administration. One-third of the proteins were identified by significantly lower spectral counts in the aqueous of the individual with moxifloxacin associated uveitis compared to the unaffected control.


Moxifloxacin was detected in aqueous humor 18 days following the completion of oral administration. These results suggest that moxifloxacin toxicity may be responsible for the uveitis-like syndrome with pigment dispersion syndrome induced by moxifloxacin therapy.